Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Caribou Biosciences, Inc.

Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Reports Third Quarter 2024 Financial Results and  Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Announces Proposed Public Offering of Common Stock
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.